Metformin use was associated with a 24% lower risk of all-cause mortality during the first six months of treatment in men with diabetes and prostate cancer compared with nonusers, a study indicated. Researchers also found that each additional six-month period of metformin treatment was tied to 44% lower odds of prostate cancer-specific mortality and a 20% decreased risk of all-cause mortality. The results appear in the Journal of Clinical Oncology.
Metformin boosts survival in men with diabetes, prostate cancer
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan